Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

A Gene Expression Signature Identifying Pro-Angiogenic Genes in Ovarian Tumor Endothelial Cell Isolates

Posted May 31 2007 5:00pm

Description of Invention:
Cancer is a heterogeneous disease that requires multimodality therapy. Most of the therapeutic approaches for ovarian cancer have focused on chemotherapy, which primarily targets proliferating tumor cells. Women with ovarian cancer are typically asymptomatic and they are often diagnosed at an advanced stage and have poor survival. Despite an 80% positive patient response rate to surgery and chemotherapy, most patients will experience tumor recurrence within two years. A majority of women who die of ovarian cancer will have ovarian epithelial carcinomas.

The inventors have discovered a unique proangiogenic biomarkers isolated from ovarian endothelial cells. By targeting tumor angiogenesis by inhibiting endothelial cells that support tumor growth, this technology provides methods to diagnose and ovarian cancer in its early stages.

Applications:
  • Method to diagnose and treat ovarian cancer in its early stage.
  • Novel early stage ovarian cancer biomarkers.
  • Therapeutic targets and compositions that inhibit ovarian tumors such as siRNA.


Development Status:
The technology is currently in the pre-clinical stage of development.

Inventors:
Michael J Birrer (NCI)


Relevant Publication:
  1. C Lu et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007 Feb 15;67(4):1757-1768. [ PubMed abs ]


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Cancer Institute’s Cell and Cancer Biology Branch, Molecular Mechanisms Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John D. Hewes, Ph.D., at 301/435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Therapeutics
Gene Based Therapies
Gene Based Therapies - Therapeutics



For Additional Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: wongje@mail.nih.gov
Phone: 301-435-4633
Fax: 301-402-0220


Ref No: 1558

Updated: 06/2007

Post a comment
Write a comment: